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Abstract
Objectives The diagnosis of shunt malfunction is often not straightforward. We have explored, in symptomatic shunted patients
with hydrocephalus or pseudotumour cerebri syndrome (PTCS), the accuracy of CSF infusion tests in differentiating a function-
ing shunt from one with possible problems, and the health economic consequences.
Methods Participants: hydrocephalus/PTCS patients with infusion tests performed from January 2013 until December 2015. We
followed patients up after 6 and 12months from the test to determine whether they had improved, had persisting symptoms or had
required urgent revision. We calculated the total cost savings of revision versus infusion tests and standard protocol of revision
and ICP monitoring versus infusion tests.
Results Three hundred sixty-five shunt infusion tests had been performed where a shunt prechamber/reservoir was present. For
hydrocephalus patients, more than half of the tests (~ 55%, 155 out of 280) showed no shunt malfunction versus 125 with
possible malfunction (ages 4 months to 90 years old). For PTCS patients aged 10 to 77 years old, 47 had possible problems and
38 no indication for shunt malfunction. Overall, > 290 unnecessary revisions were avoided over 3 years’ time. Two hundred fifty-
eight (> 85%) of those non-surgically managed, remained well, did not deteriorate and did not require surgery. No infections were
associated with infusion studies. For Cambridge, the overall savings from avoiding revisions was £945,415 annually.
Conclusions Our results provide evidence of the importance of shunt testing in vivo to confirm shunt malfunction. Avoiding
unnecessary shunt revisions carries a strong health benefit for patients that also translates to a significant financial benefit for the
National Health Service and potentially for other healthcare systems worldwide.
Keywords Cerebrospinal fluiddiversion .Hydrocephalus . Idiopathic intracranialhypertension . Infusionstudies . Pseudotumour
cerebri . Shunts . Shunt testing in vivo
Abbreviations
CSF Cerebrospinal fluid
IIH Idiopathic intracranial hypertension
PTCS Pseudotumour cerebri syndrome
CT Computed tomography
MRI Magnetic resonance imaging
e-MR Electronic medical record
Introduction
The most recent epidemiological study from the UK Shunt
Registry demonstrates that 20% of CSF shunts fail within
1 year of primary insertion, ranging from 31% in infants to
17.4% in adults (Fernandez-Mendez R et al. 2019, in press).
The main reasons for revision were underdrainage and
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infection, but overdrainage and mechanical failure continue to
pose problems. The diagnosis of shunt malfunction based on a
careful clinical history, examination, and investigations such
as computed tomography (CT) scanning and plain X-ray
shunt series, is not always straightforward [45]. For example,
ventricular size may not change in cases with a blocked shunt.
Pumping a shunt prechamber is notoriously unreliable and
potentially dangerous [5]. Admission for observation is ex-
pensive and excessive CT scanning carries a radiation burden.
Many patients may be admitted and subjected to CT scanning
on multiple occasions. There is a need to develop more reli-
able methods of assessing shunt function and monitoring in-
tracranial pressure (ICP) [18, 27, 36, 42, 44, 46]. Intrashunt
injection of a radionuclide, or creation of ultrasound bubbles
or a thermal gradient all have their advocates. Optic nerve
sheath diameter may be assessed using ultrasound or magnetic
resonance imaging (MRI). Implantable ICP sensors within a
shunt system have been blighted by poor long-term stability.
Long-term studies of the recently introduced Raumedic
Neurovent P-tel and the Miethke prechamber ICP sensor are
awaited with keen interest [1].
Non-invasive techniques to assess ‘semi-quantitatively’
whether intracranial pressure is raised or not include optic
nerve sheath diameter (ultrasound or MRI), tympanic mem-
brane displacement and transcranial Doppler but none have
yet been shown to be sufficiently accurate for routine clinical
use in patients with potential shunt malfunction.
Provision of a separate subcutaneous CSF reservoir is of
proven benefit in allowing access to the cerebral ventricles to
measure ICP and allow removal of CSF in an emergency [30].
CSF infusion tests are an elaboration of the tap-test that were
introduced into clinical practice over 45 years ago and have
been reported to be a minimally invasive, low risk and poten-
tially useful diagnostic tool for testing shunt function in vivo
[10, 13, 20, 21, 31]. However, they still lack widespread en-
dorsement. In this study, we aim to show that shunt infusion
tests are accurate in terms of differentiating between a working
shunt and a shunt with complete or partial failure such as
under-, overdrainage or blockage [6, 14, 37, 47], aid resetting
of adjustable valves, help refine shunt revision surgery and are




We identified and collected the results of all shunt infusion
tests performed between January 2013 and December 2015.
These included a total of 280 computerised CSF infusion tests
which were performed in 210 shunted hydrocephalus patients
of all ages and aetiologies. As part of our routine clinical
pathway, all shunted individuals presenting with sudden on-
set, clear symptoms of raised ICP and an unequivocal CT head
would have had an urgent revision and therefore do not re-
quire a shunt infusion test.
Besides the hydrocephalus shunt infusions, we included 85
tests on PTCS patients (including idiopathic intracranial hy-
pertension (IIH)) and analysed them separately because of
differences and more complexities compared to hydrocepha-
lus patients. However, the shunts implanted in those patients
do not differ significantly in properties and the same principles
of shunt testing in vivo apply to them as well, as infusion
objectively tests the hydrodynamic properties of the implanted
shunt.
Shunt infusion test procedure and result
interpretation
Infusion test results and conclusion on the shunt’s function
had been reported independently by a clinical physicist at
the time of request and the conclusion statement (blocked,
under-/overdraining and properly functioning) was used to
match against clinical outcome.
Objective testing of implanted shunts through infusion
studies is a well-refined method based on both in vitro and
in vivo knowledge of all marketed shunts’ hydrodynamics,
primarily the shunt critical pressure and its resistance [6, 10,
13]. Validation of the methodology in relationship to clinical
and intraoperative findings of shunt revision has recently been
performed in a large paediatric population from two European
centres [17].
Analytically, testing for underdrainage relies on the calcu-
lation of mainly the critical shunt pressure, with the baseline
pressure very occasionally being elevated in relationship to
the shunt operating pressure. The critical shunt pressure is
calculated based on the shunt resistance, infusion rate, operat-
ing pressure and average normal abdominal pressure of
5 mmHg as critical ICP (in mmHg) ≤ resistance of shunt ×
infusion rate + shunt operating pressure + 5 (abdominal pres-
sure). An illustrative example of underdrainage is shown in
Fig. 1a. In relationship to overdrainage, this can easily be
assessed by testing the siphoning effect of the shunt when
the patient is sitting upright, as well as assessing the difference
between baseline ICP and ICP after performing the tilt test
(upright position for at least 10 min until stabilisation of pres-
sure, then flat position again). A pictorial depiction of this is
shown in Fig. 1b. When the plateau pressure during infusion
of liquid and the shunt resistance are significantly higher than
the manufactured properties, combined with a higher than the
manufactured resistance and excluding increased intra-
abdominal pressure, a distal obstruction (valve and/or distal
catheter) can be suspected. The baseline ICP is usually nor-
mal, especially in cases of chronic hydrocephalus.
Occasionally, and depending on the aetiology and acuity of
1020 Acta Neurochir (2020) 162: 1019–1031
hydrocephalus, the baseline ICP can be significantly raised to
levels too high for a functioning shunt, and a distal obstruction
can be confirmed right away. Representative examples of such
distal obstructions are shown in Fig. 2a, b. A ventricular cath-
eter obstruction is accordingly observed in the absence of a
detectable ICP pulse waveform when accessing the ventricu-
lar space through insertion of needles to the reservoir or
prechamber. A classic example of proximal obstruction is
shown in Fig. 2c. Analysis can be highly diagnostic and
Fig. 1 Shunt testing results of under- and overdrainage. a Top: Normally
functioning shunt, with the plateau (steady-state) pressure after infusion
of Hartmann’s not exceeding the shunt’s critical ICP. Bottom:
Underdraining shunt, whereby the critical ICP is exceeded by a few
mmHg. The formula at the top explains how the critical ICP is calculated.
A clearly detected ICP pulsation and amplitude (AMP) confirms the
presence of communication with the ventricles, and therefore a patent
ventricular catheter. All calculated parameters are derived from the UK
shunt laboratory. b Slow phase response of decrease in ICP in an
individual without a shunt versus fast response of decrease in ICP to <
− 10 mmHg in a shunt with antisyphon device failure causing posture-
related overdrainage. After laying flat again, ICP is significantly lower
than the original baseline. ICP intracranial pressure, AMP amplitude of
intracranial pressure. Figure modified with permission from Czosnyka,
Zofia, Czosnyka, Marek, Pickard J. Shunt testing in vivo: A method
based on the data from the UK Shunt Evaluation Laboratory. Acta
Neurochir Suppl. 2002; 81:27–30
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Fig. 2 Shunt testing results of
proximal and distal obstruction. a
Distal obstruction. Upper panel:
distal obstruction detected after
infusion of fluid. Initial baseline
ICP appears normal (c. 12
mmHg); however, ICP increases
to > 25 and towards the end to >
40 mmHg, completely out of
range for a functioning distal
catheter. Lowe panel: distal
obstruction evident from initial
monitoring of baseline ICP for 15
min. The opening ICP was > 20
mmHg, spontaneously increasing
to > 30 mmHg after 5 min of
monitoring, revealing sever
intracranial hypertension caused
by a patent ventricular, however
blocked distal catheter. Infusion
was not performed as it is unsafe
in such high ICP. b Proximal
(ventricular catheter) obstruction
as evidenced by a lack of
pulsation and therefore heart rate
and amplitude detection from the
pressure inside the shunt
prechamber. This demonstrates
lack of connection with the
ventricles. Infusion can be started
as normal, and an unobstructed
distal run-off is detected through
stabilisation of pressure at the
expected critical level. All 3
patients had no or very mild
changes in their ventricular size.
Revision of the shunt confirmed
obstruction at the sites indicated
by infusion, and also confirmed
patent opposite end. ICP
intracranial pressure, HR heart
rate, AMP amplitude of ICP, RAP
compensatory reserve index
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may also suggest partial obstruction, slit ventricles, etc. [6–9,
11, 15, 23, 26].
Follow-up and outcome assessment
We carefully inspected all follow-up documentation from the
patients’ records through our local electronic medical records
(e-MR) and Epic softwares up to 6 months as well as up to
12 months from the time of the test. Searching included all
follow-up clinics, possible readmissions, revision surgeries,
inpatient notes if admitted and all reasons for the above.
Based on the documented clinical progress and consultant
impression, and mainly on the basis of relief of symptoms
with good reported quality of life at follow-up, patients were
marked as improving or non-improving.
Financial analysis
We obtained billing and tariff data from our hospital’s finance
department. For each shunt infusion study and shunt revision,
the hospital invoices the Cambridge and Peterborough
Clinical Commissioning Group (CCG) according to a fixed
tariff that has been refined over the years, locally for CSF
infusion tests and nationally for shunt revision operations.
All the calculations were made in pounds sterling (GBP).
CSF shunt infusion studies have been the Neurosurgery
Division’s standard operating procedure for over 25 years.
Hence, it was not possible to estimate, in the absence of day
case CSF infusion studies, how many patients would have oth-
erwise been managed and followed up. Therefore, in order to
assess any savings achieved through infusion studies, we have
assumed that the symptoms of all the patients would have been
sufficiently severe to require admission either for a revision or
for observation and/or ICP monitoring. Some of the patients
whowould have been admitted for observation and/or ICPmon-
itoring would have required subsequent shunt revision so that
the total cost of their inpatient management would have been the
cost of admission, ICP monitoring AND a shunt revision.
Based on the above, we designed decision trees comparing
patient flow and costs in a general neurosurgical protocol with
versus without infusion studies. Data for the decision tree
analysis were extracted from the national cost referencing
forms 2017/18.
Results
Patient demographics and overall characteristics
Patients with various forms of hydrocephalus are discussed
separately from patients with PTCS (including IIH) in the
outcomes analysis to reflect differences in their clinical course
and management.
Hydrocephalus patient group (280 tests in 210 patients):
mean age was 45 years (range 4 months to 90 years of
age) with a male to female ratio of 0.84 (93 males /207
females). Forty-seven were paediatric cases (under 16 years
of age). Overall, more than half of the tests (55%, 155 out of
280) had concluded there was no indication of shunt mal-
function whereas 125 tests underpinned a possible malfunc-
tion (over-/underdrainage or blockage).
PTCS group: 56 patients, 55 females, 1 male, aged 10 to
77 years old. Their CSF test results were as follows: 85
tests, 47 with possible problems and 38 without any in-
dication for shunt malfunction. Some patients required
more than 1 study within the selected period, therefore
from the 56 studies 12 of them had > 1 test.
Outcome for hydrocephalus patients
with normal-functioning shunt
Overall, the outcomes for hydrocephalic patients are
summarised in Fig. 3. Twenty-four of the patients are dupli-
cated in the malfunctioning and functioning group, due to
separate assessments over 12 months apart, showing different
results, but are discussed as separate cases.
6-Month outcome
13/155 tests were linked to further care needs postinfusion: 4
patients required revision before a 6-month follow-up period.
Three out of these 4 were most probably independent of the time
and the results of the study. They required revisions because of
an accident that exposed their shunt tubing (one case) or because
of distal catheter migration in the other two patients a few
months after the test. Three patients were lost in follow-up and
three more died of causes that could not be associated with
intracranial hypertension or shunt-related complications; these
were for each of the three: hip fracture, recurrence of aneurysmal
bleeding and a complex epilepsy syndrome. Lastly, three patients
with a most likely patent shunt had ongoing symptoms and were
referred for discussion in the Multidisciplinary Team meeting.
142/155 tests resulted in cases that were either discharged
from neurosurgical care with instructions or referred for head-
ache management. In some occasions, they had their shunt
setting adjusted and did not require any further neurosurgical
intervention. Five of these patients needed a longer period of
supervision and management, mostly trying to adjust their
shunts to a setting that relieved their symptoms but were man-
aged successfully without surgery. Two patients remained un-
well; one had never been well before or after shunting for NPH
 1023Acta Neurochir (2020) 162: 1019–1031
and had already previously suffered from severe overdrainage,
requiring evacuation of bilateral subdural haematomas. The
other patient appeared to suffer from refractory headaches de-
spite attempts of adjusting their shunt setting; however, they
were still managed in an outpatient basis.
Overall, 140 of the tests revealed no evident shunt malfunc-
tion on 109 unique hydrocephalic patients (27 individuals had
2 and 2 patients had 3 tests, each negative) who improvedwith
conservative management at 6 months of follow-up.
12-Month outcome
Similarly, 136 cases out of the 140 that had done well at
6 months remained well after for at least 12 months, with
the exception of 3 patients who required revision within
12–14 months after their initial infusion test, and one who
required a revision after approximately 7 months (the sin-
gle patient with refractory headaches that could not im-
prove at 6 months by setting manipulation). Three more
patients were referred for a new infusion test that showed
a problem with the shunt that required changing of the
Fig. 3 1-year outcome of patients with diagnosed hydrocephalus of
multiple aetiologies undergoing CSF infusion studies for shunt function
assessment in vivo. *1: Not improved after revision: One patient came
back with new blockage confirmed with infusion study, but improved
after the second revision. One had a wound breakdown with CSF leak
and improved after system and wound revision. Another patient
developed significant scarring with cheloids that required revision.
Three more patients remained quite unwell, with long-term ongoing in-
vestigations between neurology and neurosurgery. Two more were
discussed in MDT meeting due to some osseous and venous lesions in
further imaging. One deteriorated neurologically but the deteriorationwas
most likely due to a spinal cord syrinx, but further follow-up is not avail-
able yet. A NPH patient with complicated postshunting history never
recovered and was placed in a nursing home. Finally, there was a very
complex patient with very prolonged hospital stay that required multiple
revisions and eventually died after years of intermittent, very long
hospitalisations and very heavy problems related to her hydrocephalus
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setting and no revision, their follow-up records showing
improvement.
The reasons for revision in all these patients are illustrated
in Table 1.
Outcome of hydrocephalus patients
with evidence of shunt malfunction
In 125 cases (112 unique patients, 13 had 2 tests, each show-
ing malfunction), the infusion test detected a problem with the
shunt’s function. Those problems were underdrainage, over
drainage or distal/proximal blockage.
Analytically, there were 27 reports of underdrainage, 33 of
over drainage, 48 blocked shunts, 8 with some disturbance of
CSF dynamics (e.g. increased resistance), 1 elevated abdom-
inal pressure, 2 slit ventricles (obstructing the proximal cath-
eter but resolved after infusion) and 6 with no clear distinction
between two possible problems, 3 with either over drainage or
blockage, 1 with either slit ventricles or blockage and 2 with
burr hole valves in situ which makes the interpretation of the
results difficult due to the construction of the device [6].
Outcome after revision—6 and 12 months
Overall, 43 revision operations were performed in patients with
evidence of obstruction on infusion studies; 2 revisions as well as
2 infusions were performed in 2 patients who required revision
and their new shunts blocked shortly after surgery. For 33 of
them, the infusion study had indicated blockage (proximal, distal
or both catheters), 8 underdrainage and 2 overdrainage.
Thirty-two improved sustainably at 6 months and even
after 1 year, 5 by changing their shunt setting in the meantime.
For some of the rest, it could be possible that their setting was
changed but it was not noted in our records and some of them
were discharged or referred to neurology.
The remaining 11 patients had no change in their symp-
toms, with persisting headaches dominating in all of them. Six
had to be discussed in our MDT meeting for possible
styloidectomy, stenting, etc. Unfortunately, 5 showed no im-
provement even after their shunt setting was adjusted postsur-
gically (for a long time of follow-up, 6–12 months, even after
neurology referral).
The reasons for revision in this group of patients are illus-
trated in Table 1.
Outcome of patients with shunt malfunction
but without revision
Of the other 82/125, 1 was lost in follow-up. Four patients
were classified as non-improving. Two presented with new
episodes of seizures and had to bemanaged with antiepileptics
and the other 2 were discussed in a MDT meeting ([16, 24]).
Seventy-seven non-revised patients with conservative
management (setting manipulation or discharge/neurology re-
ferral) had improvement or acceptable control of their symp-
toms and did not require additional care for at least 1 year after
their initial encounter for infusion studies. Two of these cases
had evidence of proximal shunt obstruction but clinical indi-
cations of improvement soon after the infusion study,
sustained for at least a year, indicating resolution of the ob-
struction, most likely from flushing the proximal catheter dur-
ing infusion. One also had radiological evidence of signifi-
cantly smaller ventricles.
From the 81/82 with non-obstructive shunt malfunction and
available follow-up and the 149/155 with normal shunt function
available for follow-up, a total of 142 + 77 = 219/230 clinically
showed that they did not require revision and were symptom-
free. This translates to a 95.22% negative predictive value (NPV)
of shunt testing in vivo for excluding shunt obstruction.
Table 1 Reasons for revision
Reason for revision Functioning shunts (total = 8) Malfunctioning shunts (total = 43)
Accident 1 0




Reasons for revision in the 8 patients with infusion test not indicating shunt failure, who required revision within a
year of the test. One patient had an accident that exposed the shunt tubing, in 2 patients the distal catheter migrated
and one patient was clinically diagnosed with overdrainage and had an antisyphon device only inserted. Four
people were not improving with conservative management (turning down their setting) and further investigations
showed underdrainage, with the neurosurgeon selecting to proceed with a revision. Reasons for revision in the
group with evidence of shunt malfunction: 34 were performed due to evidence of proximal or distal obstruction
after clinical review and decision. Six patients had evident overdrainage that required an antisyphon device (2
cases) or even removal of the entire system (4 cases, due to desire to change the fixed valves with programmable
ones)
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Outcome of PTCS patients
Very few PTCS patients’ shunts were deemed as blocked after an
infusion study. Those patients have complicated courses and are
often not only considered for revision but also for stenting,
styloidectomy, temporal decompressions, etc., so we assessed
them differently, according to our aim: regardless of whether a
problemwas detected (over-/underdrainage), we found that 46 of
the patients with patent shunts were successfully managed with
no neurosurgical intervention. The conservative management
provided was the same as that for our hydrocephalus patients
and are mentioned above extensively. These patients likewise
remained well with no further care needs for at least 1 year of
follow-up.
Twelve tests led to a revision shortly afterwards, after
which 11 of them improved.
The 27 other patients investigated were found either as
non-improving, requiring multiple revisions or different sur-
geries (usually venous stenting) and closer medical attention
and discussions.
The overall outcome of PTCS patients is illustrated in
Fig. 4.
Further investigations and complications
Four hydrocephalus patients were admitted electively after the
infusion test for overnight ICP monitoring. Two of the moni-
toring sessions confirmed overdrainage (there was suspicion
but not strong evidence of overdrainage in the infusion test)
and two required assessment of ICP and it dynamics for clin-
ical and safety reasons, because a proximal obstruction did not
allow reading and recording of the ICP during the infusion
test.
Five PTCS patients were referred for ICP monitoring due
to unresolving symptoms suspicious of active disease.
Our infection rate both for acute meningitis and chronic,
subacute infections was 0%. This was assessed through pa-
tients’ medical records and revision requirements. All infec-
tions and CSF samples related to shunts are referred to
Fig. 4 1-year outcome of patients
with diagnosed pseudotumour
cerebri syndrome undergoing
CSF infusion studies for shunt
function assessment in vivo
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Cambridge regardless of local area, from all of our catchment
area on East of England.
Health economics analysis
The current financial analysis does not separate the hydro-
cephalus and PTCS groups, because there were no significant
differences in their care costs related to shunt problems.
Cost of and income received for shunt reservoir
infusion studies
The cost of day case admission for patients with possible
shunt malfunction were calculated by the Trust’s Finance
Department and included:
& Transport expenses,
& Staff: nursing, medical physics and medical staff involved,
& Cost of the shunt infusion studies equipment (including
medical equipment for shunt tapping and for the
computerised infusion study).
The total cost of each reservoir infusion study to the Trust
was 844 GBP that matched the exact income received.
Tariff for a shunt revision
Each shunt revision is billed to reflect
& Anaesthetic and theatre time,
& The medical and nursing staff involved,
& Theatre equipment and consumables including the cost of
the valve and shunt catheters,
& Total length of hospital stay, and
& The management of any postoperative complications.
The total cost of a shunt revision procedure ranged
from 9437 to 12,436 GBP (average of 10,937 GBP).
The wide range in costing is due to different comorbid-
ities that affected the cost of the surgery, as well as
perioperative complications, care needs and length of
stay.
Overall financial benefit of CSF infusion studies
From our outcome analysis data, it can be extrapolated that
(a) The total cost of 365 CSF infusion studies was £307,695
(365 × 843).
(b) The actual number and cost of shunt revision operations
was 65x£10,937 = £710,905.
(c) The total cost to the Trust of 365 studies plus actual
number of Shunt revisions = £1,007,663.
In respect of what might have happened in the absence
of a CSF infusion test service, two scenarios have been
explored: first, that all patients would have had a shunt
revision in the absence of a CSF infusion study, OR sec-
ond, that a proportion of patients admitted for observation
would have had ICP monitoring, 70% of whom would
have gone on to shunt revision (decision trees—
Fig. 5a, b).
Scenario 1
(d) The cost of shunt revision operations avoided was 299
(Figs. 3 and 4 sum of all non-revised) × £10,937 =
£3,270,163.
(e) The total cost to the Trust if no CSF infusion study ser-
vice = ~ 3,992,005 (365 × 10,937)
Scenario 2
Therefore, from all of the above, the total saving to the
Trust by providing a CSF infusion service = ~ £2,766,081
over 3 years = ~ £922,027 per annum.
When comparing infusion studies to a standard protocol,
using only ICP monitoring and exploratory surgery, the over-
all financial benefit could be approximately £442,710 per 100
patients admitted with possible shunt malfunction. An analyt-
ical decision tree showing a comparative cost analysis be-
tween using infusion studies versus no infusion studies is pre-
sented in Fig. 5.
Discussion
This study provides the first long-term, clinical outcome-
orientated evidence to support the importance of avoiding
revisions of patent shunts and optimizing shunt diagnostics
through the incorporation of infusion studies in every day
neurosurgical practice, as at the Regional Neurosurgery Unit
at Addenbrooke’s Hospital, Cambridge (catchment population
~ 3 million). Our large cohort of patients, complication-free
method and catchment population could translate to a poten-
tially high external validity and applications of our findings in
healthcare systems worldwide.
There were three main findings in our analysis:
1. The use of infusion studies as a supportive tool for clinical
decisions on shunt revision helped in avoiding over 290
(299 long-term at 12 months) unnecessary operations
over the course of 3 years.
2. 258—over 200 and around 86%—of those patients non-
surgically managed remained well long-term without
persisting symptoms or additional care requirements.
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This translates to a very high negative predictive value of
the shunt infusion test, a point which should be investi-
gated independently in a separate study.
3. A significant amount of money was saved and the burden
on patients of unnecessary shunt revision operations
averted.
Importantly, patients with normally functioning shunts
remained well after discharge or under pharmacological
care that was sufficient for their headaches. Not a single
patient presented with acute/severe problems after being
discharged and no patient’s shunt was infected as a result
of the test. It is our hospital’s policy to remove shunt sys-
tems if there is a CNS infection. If any of the above pa-
tients had an infection attributed to their shunt infusion
test, they would have been referred to the neurosurgical
team for review and management.
Infusion tests provide reliable evidence that the shunt is not
obstructed and does not allow ICP to exceed a desired range
[3, 6, 10, 14]. Patients can therefore be discharged home safely
and booked for a routine follow-up that will allow more time
and better planning to be invested into their review and care.
Hydrocephalus patients
Infusion tests appeared quite accurate and efficient in
directing away from shunt malfunction in hydrocephalus,
as demonstrated by the 212 cases that were managed con-
servatively without further hospitalisations. Shunt testing
in vivo appears to be most valuable to our selected cases
that did not have a radiological signs substantiative of
shunt malfunction and were not acutely unwell. This can
often be the case with NPH patients, as well as younger
patients with chronic or neglected hydrocephalus [2, 6, 8,
22, 23, 25, 43].
It has been highlighted in multiple reports of paediatric
hydrocephalus patients that an increased number of revi-
sion operations is a negative predictive factor for cognitive
outcome and overall disability and quality of life for pae-
diatric patients [3–6, 9, 27, 28]. For adults, this increased
number also is a predictor of further shunt revision surgery
requirements in the future and therefore constant care
needs, many hospitalisations and reduced quality of life
[3, 6, 17, 29]. Importantly, over 85% of our patients lead
a symptom-free and neurosurgically uneventful life for at
least 1 year of follow-up. Furthermore, patients were
spared the consequences of longer hospital stay and the
additional complications of unnecessary shunt revision
surgery, whose rates and sequelae have been reported ex-
tensively in the literature [18, 19, 27].
a b
Fig. 5 Elementary decision tree analysis of a costs of shunt malfunction
management without infusion studies, b costs of shunt malfunction
management as derived from our infusion study patients. Data derived
from national reference costs 2017/18 and hospital income/outcome re-
cords. On average, as derived from our dataset in Table 1, around 35% of
possible shunt malfunctions are due to shunt obstruction or are not
amendable with shunt reprogramming. Around half of the patients do
not require revision, with good resolution of symptoms. This rationale
was used to calculate costs of managing patients without shunt infusions.
The benefit of diagnostic information derived by infusions allows routine
instead of close monitoring and facilitation of differential diagnosis of
symptoms. The cost of saving follow-ups could not be approximated with
the current design and dataset from our hospital. Furthermore, panel a
cannot approximate the cost of extra hospital days in those receiving
overnight monitoring with or without revision, as it is not common or
standard practice in our centre
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PTCS patients
The pathophysiology of PTCS is complex and often in-
volves concomitant elevation of the venous sinus pressures
and CSF pressures that appeared to be coupled [12, 33, 34,
40]. However, a shunt infusion could be useful in pointing
towards or away from a shunt problem, facilitating patient
flow and referral for stenting or other management. There
were 15 patients with proven working shunts on their CSF
infusion studies whose symptoms could not be relieved
with conservative management. They were referred back
to the PTCS multidisciplinary team for further investiga-
tions and consideration of alternative treatments without
being subjected to a revision that would most likely not
have benefitted them and would have delayed their referral
to a more appropriate service.
Predictive value of the shunt infusion test
Based on the data from symptom relief and follow-up
alone, the NPVof shunt infusion tests was 95%. This refers
to the accuracy with which a shunt infusion test can ex-
clude a shunt obstruction. In order to accurately reflect the
positive predictive value as well as the NPVof the test, the
results from the intraoperative shunt flow testing should be
compared with the infusion test result. As our patients with
a negative (exclusive of obstruction) shunt infusion test
would not undergo a revision in their majority, it would
not be possible to calculate this in our current dataset.
Furthermore, as from our 51 revised patients, not all the
intraoperative notes clearly indicated the site of obstruc-
tion; the low number of patients currently tested would
not be able to yield a reliable positive predictive value.
Finally, we only calculated the NPV derived from hydro-
cephalus patients, whose clinical course as mentioned is
more straightforward, whereas PTCS patients present with
multidisciplinary challenges that confound their assess-
ment based on shunt patency alone. A new design, aiming
to test this diagnostic accuracy with a high number of re-
vised patients, should be performed to address this.
Financial impact of avoiding shunt revisions
on the NHS
Overall, the surgical management of CSF disorders is very
cost-effective in comparison with the rest of medicine in gen-
eral. The average cost per QALY was only £215 in 1990 in
comparison, for example, to £750 for a hip replacement or
£700 for a pacemaker. Length of stay has reduced consider-
ably since 1990 so that the cost per QALY will have reduced
further in relative terms. Antibiotic-impregnated shunt cathe-
ters have been shown to be cost-effective with cost savings of
$42,125 and $230,390 per 100 de novo shunts placed in adult
and paediatric patients respectively [35].
As expected, avoiding surgical revisions in shunted pa-
tients seems to be of considerable financial benefit to the
NHS. However, as stated in the methods, it is not possible
to know exactly how many of these patients would have
been selected for shunt revision, if infusion studies were
not available. There are other methods that are used world-
wide in order to diagnose shunt malfunction. Overnight
ICP monitoring remains the gold standard, but it is also
quite invasive, involves cranial surgery and has its own
cost implications. Other methods, less invasive, involve
radiation (such as radio-contrast shuntograms, radioactive
flow studies) or no radiation (MRI/high resolution MRI,
optic sheath diameter measurements, etc.). However, they
all implicate the cost of a radiologist or other highly
specialised clinical staff, expose the patient to radiation
and even endanger the functionality and/or patency of the
shunt [2, 4, 6, 10, 23]. In addition, measurements of
steady-state ICP cannot exclude shunt malfunction. No
flow through a shunt does not automatically mean obstruc-
tion, but many other things, including inadequate pressure
to open the valve or even collapsed ventricles (slit ventri-
cles) around the proximal catheter, among others [4, 6, 10,
23, 28, 29, 32, 43]. Last but not least, our current protocol
for performing shunt infusion studies that includes strict
aseptic technique and proper cleaning and disinfection ap-
pears to be 100% effective in avoiding additional costs
related to infections from the procedure.
Shunt revision is a predictive factor for multiple future
revisions; therefore, averting one redundant revision translates
to averting multiple revisions in the long-term [3, 4, 7–9, 39].
A recent report from the UK shunt registry has indicated the
revision rates in all UK centres, where our centre holds a lower
revision rate compared to the average, especially after first
implantation [41]. Another aspect considered in the revision
costs, is that the comprehensive nature of infusion studies
allows the clinical team to be aware, and not blinded to, the
location of the shunt issue. A proximal catheter obstruction
can easily be differentiated from a valve or distal catheter
problem [6, 7, 10, 11, 23, 26, 28, 32, 38]. This most probably
decreases the cost of the revision surgery, since parts of the
shunt can be left intact, decreasing surgical time, use of equip-
ment, complications and postoperative hospital stay.
However, investigating this was not within the scope of our
current paper and could be the subject of a different study.
Limitations
The main limitation of this study is that it is from a single
centre and it was unknown how many patients would have
had a shunt revision in the absence of a CSF infusion study.
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We have estimated the costs based on a 50% rate of ICP
monitoring and 70% rate of revision in this subgroup of pa-
tients (Fig. 4a). A shunt infusion study requires access to a
prechamber. This shunt anatomy is present in most valves in
the market, with the exception of the fixed-pressure burr hole
valve [6].
Acknowledgements We are very grateful to Dr. Ed Wilson (Senior lec-
turer in health economics, University of East Anglia) for his critique of
the health economics analysis of our paper. We are very grateful to Mrs.
Kathy Haynes, our former Associate Director for Clinical Neurosciences,
who enthusiastically supported the establishment of the CSF infusion
study service and highlighted the importance of a health economics ap-
proach to achieve its sustainability. Finally, we would like to thank Dr.
Rocio Fernandez Mendez for providing us data from the UK shunt
registry.
Author statement ADL drafted the manuscript, collected all data and
analysed the outcome data. MC assisted in the concept and design of
the study, as well as data analysis and contributed to writing the manu-
script. MRG assisted in analysing and interpreting the data, as well as
contributed to the final version of the manuscript. EN contributed to
collecting and analysing the data, as well as critically reviewed the man-
uscript and contributed to its final version. GP critically reviewed the
outcome analysis and contributed to writing the paper and its final ver-
sion. PJH assisted in the concept and design of the study, as well as the
analysis and collection of the outcome as well as the financial data and
contributed to the final version of the manuscript. JDP and ZC equally
contributed to the conception and design of this study and final version of
the manuscript; they also both possess expertise and previous work close-
ly related to developing and designing the current study.
Funding information PJH and MC are supported by an NIHR Research
Professorship and the NIHR Cambridge BRC. JDP was an NIHR Senior
Investigator (2009–2014) and is Honorary Director of the NIHR Brain
Injury Healthcare Cooperative (2012–2017), now MedTech Cooperative
(2018–2023).
Compliance with ethical standards
Conflict of interest MChas a partial financial interest in licencing ICM+
software, the tool used to perform and analyse infusion tests in
Cambridge.
Data statement Unfortunately, we do not possess appropriate ethics in
order to share our anonymised data from patients, as all studies were
performed on a clinical indication and at the time of consent, there was
no statement asking permission for sharing (see ethical approval
statement).
Ethics All patients consented to the use of their data recordings for
research purposes. Tests were performed on clinical indication and did
not require separate ethical committee approval, as per local guidelines.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons licence, and indicate if
changes weremade. The images or other third party material in this article
are included in the article's Creative Commons licence, unless indicated
otherwise in a credit line to the material. If material is not included in the
article's Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will
need to obtain permission directly from the copyright holder. To view a
copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References
1. Antes S, Stadie A, Müller S, Linsler S, Breuskin D, Oertel J (2018)
Intracranial Pressure–Guided Shunt Valve Adjustments with the
Miethke Sensor Reservoir. World Neurosur 642–650
2. Arrington CN,Ware AL, Ahmed Y, Kulesz PA, Dennis M, Fletcher
JM (2016) Are shunt revisions associated with IQ in congenital
hydrocephalus? a meta -analysis. Neuropsychol Rev 26(4):329–
339
3. Aylward SC, Reem RE (2017) Pediatric neurology pediatric intra-
cranial hypertension. Pediatr Neurol 66:32–43
4. Boyle TP, Nigrovic LE (2015) Radiographic evaluation of pediatric
cerebrospinal fluid shunt malfunction in the emergency setting.
Pediatr Emerg Care 31(6):435–440
5. Bromby A, Czosnyka Z, Allin D, Richards HK, Pickard JD,
Czosnyka M (2007) Laboratory study on “intracranial hypoten-
sion” created by pumping the chamber of a hydrocephalus shunt.
Cerebrospinal Fluid Res 9:1–9
6. Chari A, Czosnyka M, Richards HK, Pickard JD, Czosnyka ZH
(2014) Hydrocephalus shunt technology: 20 years of experience
from the Cambridge Shunt Evaluation Laboratory. J Neurosurg
120(3):697–707. https://doi.org/10.3171/2013.11.JNS121895
7. CzosnykaM (1996) Testing of cerebrospinal compensatory reserve
in shunted and non-shunted patients: a quide to interpretation based
on an observationl study. J Neurol Neurosurg Psychiatry
c(November 1995):549–558
8. Czosnyka M, Pickard JD (2004) Monitoring and interpretation of
intracranial pressure. J Neurol Neurosurg Psychiatry 75:813–821
9. Czosnyka M, Whitehouse H, Smielewski P, Simac S, Pickard JD
(1996) Testing of cerebrospinal compensatory reserve in shunted
and non-shunted patients: a guide to interpretation based on an
observational study. J Neurol Neurosurg Psychiatry. https://doi.
org/10.1136/jnnp.60.5.549
10. Czosnyka M, Czosnyka ZH, Momjian S, Pickard JD (2004)
Cerebrospinal fluid dynamics. Physiol Meas 25(5):R51–R76
11. Czosnyka Z, Czosnyka M, Owler B, Momjian S, Kasprowicz M,
Schmidt EA, Smielewski P, Pickard JD (2005) Clinical testing of
CSF circulation in hydrocephalus. Acta Neurochir Suppl c(95):
247–251
12. Czosnyka Z, Czosnyka M, Owler B, Momjian S, Kasprowicz M,
Schmidt EA, Smielewski P, Pickard JD (2005) Clinical testing of
CSF circulation in hydrocephalus. Acta Neurochir Suppl 95:247–
251
13. CzosnykaM, Czosnyka Z, Agarwal-harding KJ, Pickard JD (2012)
Modeling of CSF dynamics: legacy of Professor Anthony
Marmarou. Acta Neurochir Suppl 113:9–14
14. CzosnykaM, Czosnyka Z, Agarwal-harding KJ, Pickard JD (2012)
Modeling of cerebrospinal fluid dynamics: legacy of Professor
Anthony Marmarou. doi: https://doi.org/10.1007/978-3-7091-
0923-6
15. CzosnykaM, Czosnyka Z, Agarwal-harding KJ, Pickard JD (2012)
Hydrocephalus. doi: https://doi.org/10.1007/978-3-7091-0923-6
16. Dashti SR, Nakaji P, Hu YC, Frei DF, Abla AA, Yao T, Fiorella D
(2012) Styloidogenic jugular venous compression syndrome: diag-
nosis and treatment: case report. Neurosurgery 70(3):E795–E799
17. Dias SF, Lalou A, Spang R, Haas-LudeK, GarnettM, Fernandez H,
Czosnyka M, Schuhmann MU, Czosnyka Z (2019) Value of
1030 Acta Neurochir (2020) 162: 1019–1031
computerized shunt infusion study in assessment of pediatric hy-
drocephalus shunt function—a two center cross-sectional study.
Childs Nerv Syst. https://doi.org/10.1007/s00381-019-04264-3
18. Dupepe EB, Hopson B, Johnston JM, Rozzelle CJ, Oakes WJ,
Blount JP, Rocque BG (2016) Rate of shunt revision as a function
of age in patients with shunted hydrocephalus due to
myelomeningocele. Neurosurg Focus 41(November):1–6
19. Edwards NC, Engelhart L, Casamento EMH, McGirt MJ (2015)
Cost-consequence analysis of antibiotic-impregnated shunts and
external ventricular drains in hydrocephalus. J Neurosurg 122(1):
139–147
20. Ekstedt J (1977) CSF hydrodynamic studies in man. 1. Method of
constant pressure CSF infusion. J Neurol Neurosurg Psychiatry
40(2):105–119
21. Ekstedt J (1978) CSF hydrodynamic studies in man 2 normal hy-
drodynamic variables related to CSF pressure and flow. J Neurol
Psychiatry 41:345–353
22. Goeser CD, McLeary MS, Young LW (1998) Diagnostic imaging
of ventriculoperitoneal shunt malfunctions and complications.
RadioGraphics 18(3):635–651
23. Hart MG, Czosnyka M, Czosnyka ZH, Fernandes HM (2014)
Combined intracranial pressure monitoring and cerebrospinal fluid
infusion study to guide management of slit ventricle syndrome.
Pediatr Neurosurg. https://doi.org/10.1159/000358561
24. Higgins JN, Garnett MR, Pickard JD, Axon PR (2017) An evalua-
tion of styloidectomy as an adjunct or alternative to jugular stenting
in idiopathic intracranial hypertension and disturbances of cranial
venous outflow. J Neurol Surg B 78(02):158–163
25. Jorgensen J, Williams C, Sarang-Sieminski A (2016)
Hydrocephalus and ventriculoperitoneal shunts: modes of failure
and opportunities for improvement. Crit Rev Biomed Eng 44(1–
02):91–97
26. Kim D-J, Kim H, Kim Y-T, Yoon BC, Czosnyka Z, Park K-W,
Czosnyka M (2015) Thresholds of resistance to CSF outflow in
predicting shunt responsiveness. Neurol Res. https://doi.org/10.
1179/1743132814Y.0000000454
27. Korinek AM, Fulla-Oller L, Boch AL, Golmard JL, Hadiji B,
Puybasset L (2011)Morbidity of ventricular cerebrospinal fluid shunt
surgery in adults: an 8-year study. Neurosurgery 68(4):985–994
28. Lavinio A, Czosnyka Z, Czosnyka M (2008) Cerebrospinal fluid
dynamics. Eur J Anaesthesiol 25:137–141
29. Limbrick DD, Baird LC, Klimo P, Riva-Cambrin J, Flannery AM
(2014) Pediatric hydrocephalus: systematic literature review and
evidence-based guidelines. Part 4: cerebrospinal fluid shunt or en-
doscopic third ventriculostomy for the treatment of hydrocephalus
in children. J Neurosurg Pediatr 14(Suppl1):30–34
30. Lo TYM,Myles LM, Minns R (2003) Long-term risks and benefits
of a separate CSF access device with ventriculoperitoneal shunting
in childhood hydrocephalus. Dev Med Child Neurol:28–33
31. Lofgren JAN, ZwetnowN (1973) The pressure-volume curve of the
cerebrospinal fluid space in dogs. Acta Neurol Scand C:557–574
32. Nabbanja E, Pickard JD, Lalou AD, Czosnyka ZH (2018) Use of
CSF infusion studies to unblock occluded hydrocephalus ventricu-
lar shunt catheters: a preliminary report of two patients. BMJ Case
Rep bcr-2017-223861
33. Owler BK, Parker G, Halmagyi GM, Dunne VG, Grinnell V,
McDowell D, Besser M (2003) Pseudotumor cerebri syndrome:
venous sinus obstruction and its treatment with stent placement. J
Neurosurg 98(5):1045–1055
34. Owler BK, Parker G, Halmagyi GM, Johnston IH, Besser M,
Pickard JD, Higgins J (2005) Cranial venous outflow obstruction
and psudotumor cerebri syndrome. Adv Tech Stand Neurosurg 30:
107–174
35. Parker SL, Mcgirt MJ, Murphy JA, Megerian JT, Stout M,
Engelhart L (2014) Cost savings associated with antibiotic-
impregnated shunt catheters in the treatment of adult and pediatric
hydrocephalus. World Neurosurg 83(3):382–386
36. Paulsen AH, Lundar T, Lindegaard KF (2015) Pediatric hydroceph-
alus: 40-year outcomes in 128 hydrocephalic patients treated with
shunts during childhood. Assessment of surgical outcome, work
participation, and health-related quality of life. J Neurosurgery-
Pediatrics 16(6):633–641
37. Petrella G, CzosnykaM, Keong N, Pickard JD, Czosnyka Z (2008)
How does CSF dynamics change after shunting? Acta Neurol
Scand 118(3):182–188
38. Petrella G, Czosnyka M, Smielewski P, Allin D, Guazzo EP,
Pickard JD, Czosnyka ZH (2009) In vivo assessment of hydroceph-
alus shunt. Acta Neurol Scand 120(5):317–323
39. Pickard J, Bailey S, Sanderson H, Rees M, Garfield JS (1990) Steps
towards cost-benefit analysis of regional neurosurgical care. BMJ
301:629–635
40. Pickard JD, Czosnyka Z, CzosnykaM, Owler B, Higgins JN (2009)
Coupling of sagittal sinus pressure and cerebrospinal fluid pressure
in idiopathic intracranial hypertension – a preliminary report. Acta
Neurochir Suppl:283–285
41. Pickard JD, Richards H, Joannides A (2017) UK Shunt Registry
Draft Report:2017
42. Richards H, Seeley H, Pickard J (2009) Who should perform shunt
surgery? Data from the UK Shunt Registry. Cerebrospinal Fluid
Res 6:S31
43. Schuhmann MU, Sood S, McAllister JP, Jaeger M, Ham SD,
Czosnyka Z, Czosnyka M (2008) Value of overnight monitoring
of intracranial pressure in hydrocephalic children. Pediatr
Neurosurg. https://doi.org/10.1159/000131675
44. Spiegelman L, Asija R, Da Silva SL, Krieger MD, McComb JG
(2014) What is the risk of infecting a cerebrospinal fluid–diverting
shunt with percutaneous tapping? J Neurosurg Pediatr 14(4):336–
339
45. Spirig JM, Frank MN, Regli L, Stieglitz LH (2017) Shunt age-
related complications in adult patients with suspected shunt dys-
function . A recommended diagnostic workup. 1421–1428
46. Tamber MS, Klimo P, Mazzola CA, Flannery AM (2014) Pediatric
hydrocephalus: systematic literature review and evidence-based
guidelines. Part 8: management of cerebrospinal fluid shunt infec-
tion. J Neurosurg Pediatr 14(Suppl1):60–71
47. Weerakkody RA, Czosnyka M, Schuhmann MU, Schmidt E,
Keong N, Santarius T, Pickard JD, Czosnyka Z (2011) Clinical
assessment of cerebrospinal fluid dynamics in hydrocephalus.
Guide to interpretation based on observational study. Acta Neurol
Scand 124(2):85–98
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
 1031Acta Neurochir (2020) 162: 1019–1031
